Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации9997Conference ProceedingsСomplications of benign prostatic hyperplasiaEsinAleksandr Vladimirovichaleksandr-esin@mail.ruhttps://orcid.org/0000-0003-0064-1433ZolotukhinOleg Vladimirovichaleksandr-esin@mail.ruhttps://orcid.org/0000-0002-6742-3142Voronezh State Medical University named after N.N.Burdenko2712202413242431504202417062024Copyright © 2024, Esin A., Zolotukhin O.V.2024<p><em>Complications of benign prostatic hyperplasia (BPH) continue to be an important medical problem, despite the successes achieved in the treatment of this disease. One of the reasons for this problem is the lack of Russian tools for assessing patient readiness. Goal. to analyze the complications of BPH in patients, depending on the level of prostate specific antigen (PSA). Materials and methods. A study of 113 BPH patients aged 43 to 80 years who were hospitalized in the urology department for transurethral resection of the prostate gland (pancreas) was conducted. All patients had a PSA level 4 ng/ml and were divided into 3 groups. Patients of the first group had a PSA value of 1.231.23 ng/ml, the second and third - 2.440.27ng/ml and 3.530.31 ng/ml, respectively. A clinical examination of patients was carried out, with the study of complaints and anamnesis data. Nominal data were presented in the form of absolute values and relative frequencies of research objects (n,%). The assessment of the statistical significance of differences in qualitative characteristics was determined using the H2pirson criterion. Results. There were no statistically significant differences between the patients of the studied groups according to the history of epicystostomy drainage.Conclusions. In the conducted study, BPH complications were more common in patients of the second and third groups.</em></p>benign prostatic hyperplasia.доброкачественной гиперплазии предстательной железы.1.1. Доброкачественная гиперплазия предстательной железы / П.И. Раснер, А.В. Сивков, Р.Р. Харчилава // Клинические рекомендации. - Москва. - 2020. - 54 с.2.2. Патогенетическое обоснование использования ингибиторов 5-альфа редуктазы в лечении доброкачественной гиперплазии предстательной железы / О.В. Золотухин, А.В. Есин, Ю.Ю. Мадыкин // Экспериментальная и клиническая урология 2022. - Т.15. - №3. - С. 94-101; https://doi.org/10.29188/2222-8543-2022-15-3-94-1013.3. Болезни предстательной железы в Российской Федерации: статистические данные 2008-2017 гг. / О.И. Аполихин, А.В. Сивков, В.А. Комарова [и др.] // Экспериментальная и клиническая урология. - 2019. - №2. - С.4-13. 10.29188/2222-8543-2019-11-2-4-12.